{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:31:23Z","timestamp":1790242283257,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T00:00:00Z","timestamp":1406592000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/bjc.2014.418","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T16:00:05Z","timestamp":1406649605000},"page":"1132-1138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":388,"title":["Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers"],"prefix":"10.1038","volume":"111","author":[{"given":"T","family":"Golan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z S","family":"Kanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Epelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Devaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Holter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Aderka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Paluch-Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gershoni-Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hedley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gallinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,29]]},"reference":[{"key":"BFbjc2014418_CR1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/cncr.22852","volume":"110","author":"KY Bilimoria","year":"2007","unstructured":"Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS (2007) Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110: 738\u2013744.","journal-title":"Cancer"},{"key":"BFbjc2014418_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nsmb.1831","volume":"17","author":"P Bouwman","year":"2010","unstructured":"Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, Van Der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17: 688\u2013695.","journal-title":"Nat Struct Mol Biol"},{"key":"BFbjc2014418_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913\u2013917.","journal-title":"Nature"},{"key":"BFbjc2014418_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/cncr.11310","volume":"97","author":"I Cass","year":"2003","unstructured":"Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187\u20132195.","journal-title":"Cancer"},{"key":"BFbjc2014418_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","volume":"26","author":"A Chetrit","year":"2008","unstructured":"Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S (2008) Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26: 20\u201325.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014418_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1055-9965.EPI-06-0783","volume":"16","author":"FJ Couch","year":"2007","unstructured":"Couch FJ, Johnson MR, Rabe KG, Brune K, De Andrade M, Goggins M, Rothenmund H, Gallinger S, Klein A, Petersen GM, Hruban RH (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16: 342\u2013346.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFbjc2014418_CR7","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1200\/JCO.2010.34.1990","volume":"29","author":"RA Dent","year":"2011","unstructured":"Dent RA, Bristow RG (2011) In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time? J Clin Oncol 29: 2130\u20132132.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014418_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"DF Easton","year":"1999","unstructured":"Easton DF (1999) Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91: 1310\u20131316.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2014418_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/(SICI)1097-0215(19960126)65:3<284::AID-IJC2>3.0.CO;2-W","volume":"65","author":"DF Easton","year":"1996","unstructured":"Easton DF, Matthews FE, Ford D, Swerdlow AJ, Peto J (1996) Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer 65: 284\u2013294.","journal-title":"Int J Cancer"},{"key":"BFbjc2014418_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471\u20131474.","journal-title":"Ann Surg Oncol"},{"key":"BFbjc2014418_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/1078-0432.CCR-09-2434","volume":"16","author":"B Evers","year":"2010","unstructured":"Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, Edser P, Adams DJ, Wade-Martins R, Bouwman P, Jonkers J (2010) A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 16: 99\u2013108.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014418_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, Mccabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917\u2013921.","journal-title":"Nature"},{"key":"BFbjc2014418_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2008.18.5546","volume":"27","author":"CR Ferrone","year":"2009","unstructured":"Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME (2009) BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 27: 433\u2013438.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014418_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1054\/bjoc.2000.1605","volume":"84","author":"A Figer","year":"2001","unstructured":"Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, Friedman E (2001) The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer 84: 478\u2013481.","journal-title":"Br J Cancer"},{"key":"BFbjc2014418_CR15","first-page":"60","volume":"7","author":"B Friedenson","year":"2005","unstructured":"Friedenson B (2005) BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7: 60.","journal-title":"MedGenMed"},{"key":"BFbjc2014418_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/jmg.40.10.787","volume":"40","author":"RM Giusti","year":"2003","unstructured":"Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB, Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J (2003) A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 40: 787\u2013792.","journal-title":"J Med Genet"},{"key":"BFbjc2014418_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2010.33.0068","volume":"30","author":"PJ Goodwin","year":"2012","unstructured":"Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, O\u2019malley FP, Milne RL, Andrulis IL, Friedlander ML, Southey MC, Apicella C, Giles GG, Longacre TA (2012) Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol 30: 19\u201326.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014418_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","volume":"95","author":"SA Hahn","year":"2003","unstructured":"Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grutzmann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95: 214\u2013221.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2014418_CR19","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","volume":"24","author":"V Heinemann","year":"2006","unstructured":"Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946\u20133952.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014418_CR20","unstructured":"Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Available at http:\/\/seer.cancer.gov\/archive\/csr\/1975_2009_pops09\/ ."},{"key":"BFbjc2014418_CR21","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/bjc.2012.483","volume":"107","author":"J Iqbal","year":"2012","unstructured":"Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Friedman E, Llacuachaqui M, Ping S, Narod SA (2012) The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 107: 2005\u20132009.","journal-title":"Br J Cancer"},{"key":"BFbjc2014418_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643\u2013646.","journal-title":"Science"},{"key":"BFbjc2014418_CR23","first-page":"409","volume":"60","author":"G Lal","year":"2000","unstructured":"Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, Redston M, Gallinger S (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60: 409\u2013416.","journal-title":"Cancer Res"},{"key":"BFbjc2014418_CR24","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1002\/cncr.25911","volume":"117","author":"LJ Lee","year":"2011","unstructured":"Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, Tung N (2011) Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 117: 3093\u20133100.","journal-title":"Cancer"},{"key":"BFbjc2014418_CR25","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","volume":"16","author":"MA Lowery","year":"2011","unstructured":"Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D\u2019adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O\u2019reilly EM (2011) An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 16: 1397\u20131402.","journal-title":"Oncologist"},{"key":"BFbjc2014418_CR26","first-page":"3789","volume":"62","author":"KM Murphy","year":"2002","unstructured":"Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62: 3789\u20133793.","journal-title":"Cancer Res"},{"key":"BFbjc2014418_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/ng1096-188","volume":"14","author":"C Oddoux","year":"1996","unstructured":"Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K (1996) The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14: 188\u2013190.","journal-title":"Nat Genet"},{"key":"BFbjc2014418_CR28","unstructured":"Oliver GR, Sugar E, Laheru D, Diaz LA (2010) Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma. Gastrointestinal Cancers Symposium Orlando, FL, USA. January 22\u201324, 2010, Abstract no:180."},{"key":"BFbjc2014418_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng0597-17","volume":"16","author":"H Ozcelik","year":"1997","unstructured":"Ozcelik H, Schmocker B, Di Nicola N, Shi XH, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, Gallinger S, Redston M (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16: 17\u201318.","journal-title":"Nat Genet"},{"key":"BFbjc2014418_CR30","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","volume":"27","author":"E Poplin","year":"2009","unstructured":"Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O\u2019dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27: 3778\u20133785.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014418_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa070608","volume":"357","author":"G Rennert","year":"2007","unstructured":"Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357: 115\u2013123.","journal-title":"N Engl J Med"},{"key":"BFbjc2014418_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng1096-185","volume":"14","author":"BB Roa","year":"1996","unstructured":"Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14: 185\u2013187.","journal-title":"Nat Genet"},{"key":"BFbjc2014418_CR33","doi-asserted-by":"publisher","first-page":"R8","DOI":"10.1186\/bcr658","volume":"6","author":"ME Robson","year":"2004","unstructured":"Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, Foulkes WD (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1\/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6: R8\u2013R17.","journal-title":"Breast Cancer Res"},{"key":"BFbjc2014418_CR34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/clinchem\/43.1.24","volume":"43","author":"EM Rohlfs","year":"1997","unstructured":"Rohlfs EM, Learning WG, Friedman KJ, Couch FJ, Weber BL, Silverman LM (1997) Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43: 24\u201329.","journal-title":"Clin Chem"},{"key":"BFbjc2014418_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.hoc.2010.06.007","volume":"24","author":"MA Shah","year":"2010","unstructured":"Shah MA, Kurtz RC (2010) Upper gastrointestinal cancer predisposition syndromes. Hematol Oncol Clin North Am 24: 815\u2013835.","journal-title":"Hematol Oncol Clin North Am"},{"key":"BFbjc2014418_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4161\/cbt.12.3.16292","volume":"12","author":"A Sonnenblick","year":"2011","unstructured":"Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A (2011) Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 12: 165\u2013168.","journal-title":"Cancer Biol Ther"},{"key":"BFbjc2014418_CR37","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","volume":"26","author":"DS Tan","year":"2008","unstructured":"Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME (2008) \u201cBRCAness\u201d syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26: 5530\u20135536.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014418_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1471-4914(02)02434-6","volume":"8","author":"A Tutt","year":"2002","unstructured":"Tutt A, Ashworth A (2002) The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8: 571\u2013576.","journal-title":"Trends Mol Med"},{"key":"BFbjc2014418_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1101\/sqb.2005.70.012","volume":"70","author":"AN Tutt","year":"2005","unstructured":"Tutt AN, Lord CJ, Mccabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70: 139\u2013148.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"BFbjc2014418_CR40","doi-asserted-by":"publisher","first-page":"7508","DOI":"10.1158\/1078-0432.CCR-05-1048","volume":"11","author":"MS van der Heijden","year":"2005","unstructured":"van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, Demarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE (2005) In vivo therapeutic responses contingent on Fanconi anemia\/BRCA2 status of the tumor. Clin Cancer Res 11: 7508\u20137515.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014418_CR41","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","volume":"22","author":"PM Vencken","year":"2011","unstructured":"Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, Berns EM, Jager A, Collee M, Burger CW, Seynaeve C (2011) Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 22: 1346\u20131352.","journal-title":"Ann Oncol"},{"key":"BFbjc2014418_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171\u2013182.","journal-title":"Cell"},{"key":"BFbjc2014418_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00018-011-0809-0","volume":"69","author":"MA Vollebergh","year":"2012","unstructured":"Vollebergh MA, Jonkers J, Linn SC (2012) Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell Mol Life Sci 69: 223\u2013245.","journal-title":"Cell Mol Life Sci"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2014418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014418","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T09:25:05Z","timestamp":1684401905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2014418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,29]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFbjc2014418"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.418","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,29]]},"assertion":[{"value":"10 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}